Target intelligence / Profile preview

Gastrointestinal microbiome and gut mucosal ecosystem (GM)

Target
GM
Molecular classification
Biological system, Ecosystem, Microbiota
01

Overview

The gastrointestinal microbiome and gut mucosal ecosystem represent a complex community of trillions of microorganisms, including bacteria, fungi, viruses, and archaea, residing within the human digestive tract (NIH, 2023). This ecosystem plays a fundamental role in host health by facilitating the digestion of complex carbohydrates, synthesizing essential vitamins, and training the mucosal immune system to distinguish between commensal organisms and pathogens (Guinane & Cotter, 2013). Dysbiosis, or the imbalance of this microbial community, is strongly linked to a wide range of local and systemic pathologies, including inflammatory bowel disease, metabolic disorders, and susceptibility to enteric infections (Fan & Pedersen, 2021). Therapeutic interventions targeting this system range from broad-spectrum antibiotics and fecal microbiota transplantations to more refined live biotherapeutic products and prebiotics designed to restore ecological balance (FDA, 2023). Understanding the intricate crosstalk between the gut microbiota and the host's mucosal barrier is critical for developing precision medicines that can modulate this ecosystem to treat chronic inflammatory and infectious diseases.

Other names
Gut microbiotaIntestinal microbiomeGut floraGastrointestinal microbiotaGut mucosal ecosystem
02

Mechanism of action

Modulation of microbial composition through competitive exclusion, restoration of ecological diversity, and production of metabolites that influence host signaling and immune function.

03

Biological functions

Nutrient metabolismImmune system maturationPathogen protectionIntestinal barrier maintenanceSynthesis of vitamins and short-chain fatty acids (SCFAs)
04

Disease associations

Inflammatory bowel disease (IBD)Irritable bowel syndrome (IBS)Clostridioides difficile infection (CDI)ObesityType 2 diabetesColorectal cancerNonalcoholic fatty liver disease (NAFLD)
05

Safety considerations

Risk of bacteremia in immunocompromised hostsTransfer of antibiotic resistance genesPotential for unintended metabolic or immunological shiftsLack of standardization in live biotherapeutic products
06

Interacting drugs

Vancomycin

6 more in the full profile.

07

Biomarkers

Microbial alpha-diversityShannon indexFirmicutes/Bacteroidetes ratioFecal calprotectinShort-chain fatty acid levels

Beyond the preview

Go deeper on Gastrointestinal microbiome and gut mucosal ecosystem (GM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastrointestinal microbiome and gut mucosal ecosystem (GM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call